-
公开(公告)号：US20100158815A1
公开(公告)日：2010-06-24
申请号：US12613400
申请日：2009-11-05
IPC分类号： A61B8/08
CPC分类号： A61K49/222 , A61B8/481
摘要： This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.
摘要翻译： 本发明解决了如何优化基于生物细胞的疗法（如干细胞治疗）的临床问题。 目前，通过静脉内，动脉内和/或直接组织注射施用的细胞疗法受到缺乏临床可用的成像方法的限制，以检测所施用细胞的体内命运。 目前正在开展许多努力来开发体内干细胞成像策略，包括放射性核素和基于MRI的方法。 然而，这些方法受到潜在安全问题的限制（例如干细胞的放射性暴露，用于MRI的铁颗粒的毒性）以及由于复杂的仪器和/或对重复辐射暴露的要求而导致的串行跟踪困难。
-
公开(公告)号：US08460269B2
公开(公告)日：2013-06-11
申请号：US12880807
申请日：2010-09-13
申请人： Catalin Toma , Flordeliza Villanueva , William Richard Wagner , Joon S. Lee , Jianjun Wang , Xucai Chen , Andrew Fisher
发明人： Catalin Toma , Flordeliza Villanueva , William Richard Wagner , Joon S. Lee , Jianjun Wang , Xucai Chen , Andrew Fisher
IPC分类号： A61M31/00
CPC分类号： A61M37/0092 , A61K35/44 , A61N7/022 , A61N2007/0039
摘要： The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.
摘要翻译： 所公开的技术描述了可用于提供基于细胞的治疗的组合物和方法。 例如，基于细胞的疗法的一个实施方案涉及损伤组织的再生和/或促进伤口愈合。 某些实施方案通过将生物祖细胞递送到受损组织来提供使用微泡的改进的治疗组合物。 微泡的施用由与包括声学活性气体的微泡的实施方案相互作用的声辐射力引导。 因此，实现了对损伤组织的高效祖细胞传递。 该技术优于药物化合物的靶向递送的一个优点是所递送的祖细胞可能来源于患者（即个体化治疗），从而避免与屈光药物反应相关的副作用，过敏反应和总体问题。
-
公开(公告)号：US08940277B2
公开(公告)日：2015-01-27
申请号：US12613400
申请日：2009-11-05
CPC分类号： A61K49/222 , A61B8/481
摘要： This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.
摘要翻译： 本发明解决了如何优化基于生物细胞的疗法（如干细胞治疗）的临床问题。 目前，通过静脉内，动脉内和/或直接组织注射施用的细胞疗法受到缺乏临床可用的成像方法的限制，以检测所施用细胞的体内命运。 目前正在开展许多努力来开发体内干细胞成像策略，包括放射性核素和基于MRI的方法。 然而，这些方法受到潜在安全问题的限制（例如干细胞的放射性暴露，用于MRI的铁颗粒的毒性）以及由于复杂的仪器和/或对重复辐射暴露的要求而导致的串行跟踪困难。
-
公开(公告)号：US09844504B2
公开(公告)日：2017-12-19
申请号：US13640954
申请日：2011-04-15
CPC分类号： A61K9/0002 , A61K9/0009 , A61K9/127 , A61K9/1272 , A61K41/0028 , A61K48/0075 , A61K48/0083 , A61N7/00 , A61N2007/0039 , B65D25/00 , C12N15/111 , C12N15/1138 , C12N15/87 , C12N15/88 , C12N2310/14 , C12N2320/32
摘要： The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction. Such systems are useful in therapeutics and/or diagnostics. For example, the data disclosed herein shows proof of principle in conjunction with the delivery of therapeutic siRNA molecules to slow tumor growth.
-
公开(公告)号：US20110208113A1
公开(公告)日：2011-08-25
申请号：US12880807
申请日：2010-09-13
申请人： Catalin Toma , Flordeliza Villanueva , William Richard Wagner , Joon S. Lee , Jianjun Wang , Xucai Chen , Andrew Fisher
发明人： Catalin Toma , Flordeliza Villanueva , William Richard Wagner , Joon S. Lee , Jianjun Wang , Xucai Chen , Andrew Fisher
CPC分类号： A61M37/0092 , A61K35/44 , A61N7/022 , A61N2007/0039
摘要： The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.
摘要翻译： 所公开的技术描述了用于提供基于细胞的治疗的组合物和方法。 例如，基于细胞的疗法的一个实施方案涉及损伤组织的再生和/或促进伤口愈合。 某些实施方案通过将生物祖细胞递送到受损组织来提供使用微泡的改进的治疗组合物。 微泡的施用由与包括声学活性气体的微泡的实施方案相互作用的声辐射力引导。 因此，实现了对损伤组织的高效祖细胞传递。 该技术优于药物化合物的靶向递送的一个优点是所递送的祖细胞可能来源于患者（即个体化治疗），从而避免与屈光药物反应相关的副作用，过敏反应和总体问题。
-
-
-
-
搜索结果
5 条记录 (耗时 0.019 秒)
